CureVac (NASDAQ:CVAC) Shares Down 5.6%

Shares of CureVac (NASDAQ:CVAC - Get Free Report) traded down 5.6% during trading on Wednesday . The stock traded as low as $3.34 and last traded at $3.34. 533,098 shares were traded during trading, a decline of 47% from the average session volume of 998,294 shares. The stock had previously closed at $3.54.

Analyst Ratings Changes

Several research analysts have recently weighed in on CVAC shares. Leerink Partnrs cut shares of CureVac from an "outperform" rating to a "market perform" rating in a report on Thursday, April 25th. SVB Leerink lowered shares of CureVac from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $12.00 to $4.00 in a research note on Thursday, April 25th. Finally, Guggenheim reissued a "neutral" rating on shares of CureVac in a research note on Friday, April 5th.

CureVac Stock Down 4.9 %

The company has a current ratio of 2.25, a quick ratio of 2.09 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $753.36 million, a P/E ratio of -2.50 and a beta of 2.68. The firm's 50 day moving average price is $3.36 and its two-hundred day moving average price is $3.54.

CureVac (NASDAQ:CVAC - Get Free Report) last released its earnings results on Thursday, May 23rd. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.12). CureVac had a negative net margin of 463.49% and a negative return on equity of 49.22%. The business had revenue of $13.43 million during the quarter, compared to the consensus estimate of $14.51 million. Equities research analysts forecast that CureVac will post -1.11 EPS for the current year.

Institutional Trading of CureVac

Hedge funds and other institutional investors have recently modified their holdings of the stock. Swiss National Bank grew its stake in CureVac by 1.8% in the third quarter. Swiss National Bank now owns 221,406 shares of the company's stock valued at $1,462,000 after purchasing an additional 3,925 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of CureVac by 351.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 25,887 shares of the company's stock valued at $109,000 after buying an additional 20,149 shares during the last quarter. Deutsche Bank AG grew its stake in shares of CureVac by 5.1% in the third quarter. Deutsche Bank AG now owns 72,510 shares of the company's stock valued at $495,000 after buying an additional 3,491 shares in the last quarter. Vanguard Personalized Indexing Management LLC acquired a new position in CureVac during the fourth quarter worth $68,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its position in CureVac by 45.0% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 44,122 shares of the company's stock worth $184,000 after acquiring an additional 13,687 shares in the last quarter. Institutional investors and hedge funds own 17.26% of the company's stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.